Top Health Tech Companies With Best Stability & Growth (8,808)
Headway’s mission is a big one – to build a new mental health care system everyone can access. We’ve built technology that helps people find great therapists with the first software-enabled national network of providers accepting insurance. 1 in 4 people in the US have a treatable mental health condition, but the majority of providers don’t accept insurance, making therapy...
Headway's Top Stability & Growth Strengths
Investor Backing & Capital Strength: The company raised a $100 million Series D in July 2024 led by Spark Capital at about a $2.3 billion valuation, roughly double its prior mark. Management indicated a clear line of sight to profitability, and continued investments such as the 2026 Tezi acqui-hire signal capacity to deploy capital.
Market Expansion: Headway reported growing its provider community to 48,000+ in 2024 and more than doubled its in‑network health plans between October 2023 and July 2024. Medicare Advantage expansion across all 50 states by late 2024, with MA guidance still active in April 2026, indicates ongoing rollout.
Innovation-Driven Growth: The company expanded its EHR with AI‑assisted tools in 2025 to deepen provider workflow support. In March 2026 it acquired the team behind AI startup Tezi, reinforcing continued product build‑out.
.png)
GRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL is using the power of high-intensity sequencing, population-scale clinical studies, and state-of-the-art computer science and data science to enhance the scientific understanding of cancer biology, and to develop and commercialize pioneering products.
GRAIL's Top Stability & Growth Strengths
Strong Revenue Growth: Recent disclosures show rising total revenue and accelerating Galleri test volumes year over year, with both full‑year 2025 and early 2026 reporting continued momentum. Quarterly updates point to sustained double‑digit growth across revenue and volumes.
Strategic Partnerships: Announcements detail deeper channel integrations and access, including Epic EHR ordering, Quest connectivity, and collaborations with health systems, employers, and digital‑health platforms. International arrangements, such as a Samsung collaboration and a Canada launch, further extend reach.
Investor Backing & Capital Strength: The company secured additional financing in late 2025 and reports a cash position described as providing a multi‑year runway. Public company status post‑spin‑off offers direct access to capital markets to fund commercialization and regulatory efforts.
Cohere Health’s clinical intelligence platform and agentic AI-powered solutions connect health plans’ strategic goals and providers’ needs, optimizing the speed, cost, and quality of care. With an enterprise approach that streamlines payer-provider decision-making across the care continuum–including policy, prior authorization, payment accuracy, and more–the company improves collaboration and reduces burden, resulting in up to 8x ROI and 94% provider satisfaction....
Cohere Health's Top Stability & Growth Strengths
Investor Backing & Capital Strength: Multiple funding rounds, including a $90M Series C in May 2025 led by Temasek, indicate robust capital support to scale AI and go-to-market. Active acquisition activity alongside ongoing hiring signals ample runway to execute growth plans.
Product Line Growth: Expansion beyond prior authorization into payment integrity via the ZignaAI acquisition and new offerings (e.g., claims intelligence, policy tools, acute inpatient capabilities) broadens the addressable market. These moves suggest a larger product surface area to capture additional payer workflows.
Strong Revenue Growth: Company communications highlight record 2025 growth, and an external revenue estimate for 2024 alongside a Deloitte Fast 500 ranking point to accelerating topline momentum. Industry lists like the Inc. 5000 further corroborate rapid business expansion.
Biotechnology is rewriting life as we know it, from the medicines we take, to the crops we grow, and the household goods that we rely on every day. But moving at the new speed of science requires better technology. Benchling’s mission is to unlock the power of biotechnology. The world’s most innovative biotech companies use Benchling’s R&D Cloud to power the...
Benchling's Top Stability & Growth Strengths
Strong Revenue Growth: Independent estimates point to continued ARR increases since 2022, with momentum remaining positive despite a slower pace than earlier hyper‑growth. Feedback suggests growth is ongoing and more disciplined rather than stagnating.
Product Line Growth: Company materials describe hundreds of new capabilities and AI‑powered tools launched through 2024–2025, alongside expanded modules and integrations. This sustained shipping cadence indicates continued investment and expansion of the platform’s surface area.
Strategic Partnerships: Named enterprise announcements include Novonesis adopting the platform across 1,500 scientists and an expanded collaboration with Moderna focused on AI‑driven research. These wins suggest ongoing enterprise adoption and deepening ties with marquee biopharma.
Cencora is a leading pharmaceutical solutions organization centered on improving the lives of people and animals everywhere. With 46,000+ global team members, we have the opportunity to make a positive impact on healthcare in communities everywhere. Our team members are empowered to activate their careers through a collective of tools and resources designed to support individual career interests and...
Cencora's Top Stability & Growth Strengths
Strong Revenue Growth: Revenue rose 9.3% year over year to $321.3B in FY2025, with FY2026 Q1 up 5.5% to $85.9B and Q2 up 3.8% to $78.4B.
Profitability: Management raised FY2026 adjusted EPS to $17.70–$17.90 and targets 12–14% adjusted operating income growth; Q2 FY2026 adjusted gross profit rose 15.7% and operating income grew 10.3%.
Investor Backing & Capital Strength: The quarterly dividend was increased by 9% in November 2025, and the company plans approximately $1B of buybacks by end of 2026 with a new $2B authorization announced May 20, 2026.
Nourish is on a mission to improve people’s health by making it easy to eat well. Nutrition-related chronic disease is the largest and most overlooked crisis in the world. Food can be medicine: working with a Registered Dietitian is one of the most effective interventions available, but <1% of eligible Americans use their covered benefits. Nourish is building an AI-native,...
Nourish's Top Stability & Growth Strengths
Investor Backing & Capital Strength: A recent $100M Series C following prior rounds brings total funding to about $215M, indicating strong capacity to scale. A 2025 valuation milestone around $1B reinforces sustained investor confidence.
Strong Revenue Growth: Revenue reportedly reached $111.9M in 2024 with consistent year-over-year increases since launch. Company communications describe continued momentum into 2025–2026.
Market Expansion: The clinical network expanded rapidly to thousands of W‑2 dietitians across all 50 states and a broader pool cited at 10,000+ RDs, enabling nationwide access. Partnerships with hundreds of health plans covering over 200 million Americans and completion of millions of appointments signal widening reach.
We are a purpose driven healthcare technology company passionate about innovation and using technology to help people by solving real world problems. The ALIS team designs, builds, delivers, and supports our flagship product ALIS (pronounced “Alice” and stands for Assisted Living Integrated Solution).
ALIS's Top Stability & Growth Strengths
Product Line Growth: Recent launches such as ALIS 500 benchmarking, the ALIS 500 Clinical Report, Ask ALIS (AI assistant), and ALIS HQ indicate active expansion of offerings. Release notes through 2025–2026 and new modules reflect a sustained shipping cadence.
Innovation-Driven Growth: AI and data initiatives (e.g., Ask ALIS and benchmarking built from hundreds of communities’ data) show investment in differentiated capabilities. Partners initially launching new workflows with ALIS further signal innovation pull.
Strategic Partnerships: Announced integrations with CarePredict and other ecosystem vendors, NIC MAP Vision certification, and an open‑API/app‑store approach point to a growing partner network. Support materials cite additional integrations consistent with deeper enterprise adoption.
TigerConnect is healthcare’s most widely adopted communication platform – uniquely modernizing care collaboration among doctors, nurses, care teams, and patients. TigerConnect is the only solution that combines a consumer-like user experience for both clinical and patient communication with serious security, privacy, and clinical workflow requirements that today’s healthcare organizations demand. TigerConnect accelerates productivity, reduces costs, and improves patient outcomes. Trusted...
TigerConnect's Top Stability & Growth Strengths
Product Line Growth: New offerings for pre‑hospital/transfer workflows and a hospital operator modernization tool launched in 2025–2026, and acquisitions of Twiage (2024) and eVideon (2025) expanded coverage into EMS coordination and smart‑room/patient engagement. These moves indicate ongoing R&D investment and a broadened set of addressable use cases.
Strong Market Position & Advantage: Repeated recognition in Gartner’s Clinical Communication & Collaboration reports and strong G2 rankings, alongside reported message volumes in the tens of millions per day, point to large, active deployments. These signals suggest durable category presence relative to peers.
Investor Backing & Capital Strength: Prior backing from Vista Equity Partners and a 2025 CEO transition framed as a new chapter of innovation and growth reflect access to capital and ambition to scale. These factors align with the cadence of launches and acquisitions cited.
Formation Bio is a tech-driven pharma company differentiated by radically more efficient drug development. Formation Bio has built a technology platform that optimizes all aspects of drug development, enabling more efficient trial design, faster trial completion, and higher quality trial data capture. Formation Bio acquires clinical-stage drugs from pharma and biotech and develops them faster and more efficiently, unlocking greater...
Formation Bio's Top Stability & Growth Strengths
Investor Backing & Capital Strength: Evidence shows a $372M Series D in June 2024 led by a16z with Sanofi participation, one of the larger biotech financings that year. The capital is framed as fuel for acquiring or in-licensing assets and expanding AI capabilities, signaling strong investor confidence.
Strategic Partnerships: A three‑way collaboration with Sanofi and OpenAI announced in May 2024 to build AI software for drug development highlights high‑profile external alignment. Additional partnered activity, such as the 2025 Sanofi deal for gusacitinib, illustrates the company’s model in practice.
Product Line Growth: Since 2025 the portfolio expanded via in‑licensing and asset‑centric subsidiaries, including an anti‑CD226 mAb (IMIDomics), a miR‑124 activator (Kenmare Bio), and ex‑China rights to a CNS‑penetrant TYK2 inhibitor from Lynk. A planned Phase 1 start in H1 2026 underscores near‑term pipeline progression.
Vetcove is a Y Combinator and venture-backed growth stage company with notable investors in Silicon Valley and NYC. Our mission is to provide veterinary hospitals and nonprofits with technology that helps them succeed through our eCommerce and mobile platforms. Our community includes more than 17,000 veterinary hospitals and nonprofits whose staff collectively deliver care to tens of millions of animals...
Vetcove's Top Stability & Growth Strengths
Market Expansion: Company materials and third‑party references indicate clinic adoption rising from about 13,000 in 2022 to 23,000+ currently, with claims of serving the majority of U.S. practices. Ongoing hiring and broader ecosystem integrations align with a scaling footprint across all 50 states.
Product Line Growth: The platform has expanded beyond procurement into a Home Delivery pharmacy and is rolling out integrations with major practice‑management systems (e.g., IDEXX Neo/ezyVet, DaySmart Vet). This broadening of capabilities supports deeper embedding in day‑to‑day clinic workflows.
Diversified Revenue Streams: While the core is free for independent clinics, Vetcove monetizes corporate groups and vendors via premium services (e.g., Inner Circle) and seller fees. This two‑sided model suggests growing enterprise and vendor revenue alongside the free tier.
AcuityMD is the intelligence platform for the MedTech industry. More than 300 MedTech companies – including six of the top 10 – use AcuityMD to identify target markets, surface top opportunities, and grow their business. With customers ranging from pre-commercial to enterprise, AcuityMD is committed to delivering the right insights so companies can understand where and how to sell faster...
AcuityMD's Top Stability & Growth Strengths
Investor Backing & Capital Strength: Recent large funding rounds (an $80M Series C in April 2026 following a $45M Series B in 2024) and coverage noting a near-$1B valuation indicate strong investor support and ample capital to scale. Sequential financings across 2024–2026 signal continued access to growth funding.
Strong Market Position & Advantage: Adoption by 16 of the top 20 MedTech companies and a customer count moving from 300+ to over 400 suggest deepening enterprise penetration. These signals align with a platform gaining prominence among leading industry players.
Innovation-Driven Growth: Expansion from commercial intelligence into AI-enabled and agentic-AI workflows, along with new modules and integrations tied to the 2026 raise, reflects active product development. This broadening of capabilities supports wider use cases across sales, leadership, and marketing.
Dandy is transforming the massive ($400B) but antiquated dental industry. Backed by some of the world's leading venture capital investors, we’re building custom, end-to-end, precision software and manufacturing from the ground up to provide high-quality, consistent, and affordable restorations to our doctors and their patients. 2 million people already have a Dandy product in their mouth and that number is...
.jpg)
Dandy's Top Stability & Growth Strengths
Product Line Growth: Recent launches of the Dandy Vision intraoral scanner, AI Scan Review, and the Dandy Cart workstation across late 2025–early 2026 indicate active expansion of the product portfolio and sustained R&D investment.
Market Expansion: Claims of thousands of dentists using the platform, active hiring signals, and a new state‑of‑the‑art Utah digital lab point to scaling customer reach and increased production capacity.
Future-Ready Strategy: The acquisition of Neem to broaden into practice management software, paired with DSO‑focused tools and facility build‑outs, suggests a platform strategy to deepen chair‑to‑lab integration.
Kalderos is a data infrastructure and analytics company that’s solving challenges around drug discounts in the U.S. healthcare system. Through platform technology and big data, our team is delivering smart solutions that enable healthcare stakeholders to collaborate with greater transparency and trust. We’re passionate about our mission to take on the most stubborn challenges in healthcare. We also know that...
Kalderos's Top Stability & Growth Strengths
Investor Backing & Capital Strength: Recent funding trackers indicate a fresh 2025 round of about $26.35M, bringing total capital raised to roughly $76M—providing fuel to scale product and go‑to‑market.
Market Expansion: Multiple 2025–2026 manufacturer and distributor notices show transitions to Truzo (e.g., Alkermes, Organon, Gilead via Cencora). These migrations suggest growing adoption across stakeholders.
Product Line Growth: Kalderos promotes Truzo as an end‑to‑end drug discount management platform and continues to enhance solutions like Discount Hub and Commercial Discount Monitoring. Industry commentary and company materials highlight expanding capabilities aligned to today’s 340B environment.
Laudio empowers healthcare leaders to drive large-scale change through everyday human actions. Our platform streamlines workflows for frontline leaders, strengthens interpersonal connections, and aligns C-suite objectives with frontline efforts, enhancing leader efficiency, employee engagement, and patient experience. Laudio makes it possible for patients, frontline workers, and health system leaders to thrive together. Discover how at www.laudio.com.
Laudio's Top Stability & Growth Strengths
Market Expansion: Public announcements describe rollouts across many hospitals and health systems, including enterprise expansions at large providers, indicating a widening footprint. The Ascend Learning acquisition is framed as expanding distribution and reach across a broader healthcare‑workforce portfolio.
Product Line Growth: After the acquisition, Laudio introduced AI‑powered Performance Insights and added modules like patient rounding. Continued capability releases indicate an expanding platform rather than a static offering.
Strategic Partnerships: The September 2025 acquisition by Ascend Learning embeds Laudio within a larger healthcare‑workforce ecosystem with added go‑to‑market leverage. Collaborations with major health systems and professional organizations are presented as amplifying impact and access.
Marble Health is building the operating system for youth mental health. A platform that connects schools, therapists, health plans, and families - who all have incentives to provide truly effective care to kids struggling with their mental health. Our mission is simple but ambitious: make it dramatically easier for young people to get the mental health care they need, and...
Marble Health's Top Stability & Growth Strengths
Investor Backing & Capital Strength: Recent $15.5M Series A led by recognized investors is cited as fuel to scale access, expand operations, and invest in product. Feedback suggests this financing underpins continued hiring and multi-state rollout.
Market Expansion: Expansion beyond New York into states like Ohio and New Jersey and growing school-district partnerships indicate a widening footprint. Feedback suggests ongoing district announcements and state coverage are expected to continue post-Series A.
Strategic Partnerships: Direct partnerships with school districts and a model that accepts most commercial and Medicaid plans position the company to accelerate uptake in K‑12. Feedback suggests payer integrations and school workflows are central to its go-to-market.
At Inato, we’re on a mission to accelerate the pace of medical innovation by bringing clinical research to each and every patient, regardless of who they are and where they live. Our platform, made to connect community-based research centers to trials across the globe, aims to create greater visibility, access, and engagement across a more diverse population of doctors and...
Inato's Top Stability & Growth Strengths
Market Expansion: Public disclosures show the site network rising from 5,500+ in September 2025 to 6,000+ across 50+ countries with 25+ sponsors by 2026, indicating steady expansion. Partnerships that add distribution—such as the RealTime eClinical tie-up covering 50+ networks and 2,000+ sites—further broaden reach.
Innovation-Driven Growth: In 2025 the company launched AI patient pre-screening and AI site-selection to accelerate enrollment and improve selection, with 2026 content highlighting added integrations and case studies. The CEO characterized these capabilities as the “biggest boost” to growth.
Investor Backing & Capital Strength: In March 2023 the company raised a $20M Series A2 to fund product innovation, international growth, and hiring. This capital base supports continued go-to-market and platform expansion.
Flume Health is a software company that connects the fragmented healthcare data ecosystem for more efficient health plan administration. As a single, cloud-native integration platform, Flume’s Relay platform allows companies to easily connect various systems and vendors for efficient data exchange that’s increasingly demanded of the modern health plan. Payers, third-party administrators, prescription benefits managers, and health solutions are provided...
Flume Health's Top Stability & Growth Strengths
Investor Backing & Capital Strength: Funding led by Optum Ventures with participation from Cigna Ventures in 2022 signals strong capitalization for continued product buildout; feedback suggests this has supported platform investment post‑pivot.
Product Line Growth: The launch of Flume Relay and ongoing platform development indicate expansion of the company’s integration capabilities; feedback suggests compliance milestones like HITRUST are enabling enterprise‑grade deployments.
Future-Ready Strategy: The 2023 pivot from TPA operations to a payer data/integration platform, coupled with HITRUST certification, points to preparation for larger payer integrations; feedback suggests the company is aligning to enterprise interoperability needs.
Schrödinger is a leading provider of advanced molecular simulations and enterprise software solutions and services for pharmaceutical, biotechnology, and materials science research. The predictive power of Schrödinger's software allows scientists to accelerate their research and development, reduce research costs, and make novel discoveries.
Schrödinger, Inc.'s Top Stability & Growth Strengths
Strong Revenue Growth: Full-year 2025 total revenue increased with software up and drug discovery roughly doubling, and early 2026 showed continued expansion in underlying annual contract value with management guiding higher for the year.
Strategic Partnerships: Multiple new and expanded pharma collaborations and progress in co‑founded companies (e.g., an announced acquisition and positive clinical readouts) provide potential milestone and equity upside that supports growth.
Future-Ready Strategy: The accelerated shift from on‑premises licenses to hosted, ratable contracts aims to increase predictability, complemented by new offerings such as predictive toxicology and an agentic AI co‑scientist to deepen adoption.
Our purpose ensures that patients remain at the center of all we do. We live our purpose by sourcing the best science in the world; partnering with others in the healthcare system to improve access to our medicines; using digital technologies to enhance our drug discovery and development, as well as patient outcomes; and leading the conversation to advocate for...
Pfizer's Top Stability & Growth Strengths
Product Line Growth: Company reports that launched and acquired products, including new oncology assets like Padcev, are contributing meaningful growth and momentum. Underlying non‑COVID revenue is increasing, with oncology and other recent launches adding to the base.
Cost & Operational Efficiency: Management indicates cost realignment and manufacturing programs are on track to deliver about $5.7B net savings by end‑2026, supporting margins and reinvestment. These measures provide capacity to fund launches and offset headwinds.
Future-Ready Strategy: The company highlights a sizable late‑stage pipeline and recent strategic acquisitions in oncology and obesity aimed at higher‑growth categories. Plans for numerous pivotal study starts in 2026 and continued pipeline investment position the business for longer‑term growth.
.png)
Garner Health is a health tech startup that is transforming the healthcare economy by enabling patients to receive high-quality and affordable care. Garner Health has two core offerings: Garner, a benefit program that uses a new approach to data science and incentive accounts to help employees find the best doctors in their communities, and Garner DataPro, a provider recommendation platform...
Garner Health's Top Stability & Growth Strengths
Investor Backing & Capital Strength: A large Series D round in February 2026 led by a top-tier investor at a unicorn valuation signals strong capital support. The new funding is described as runway for headcount, product development, and market expansion.
Strong Revenue Growth: Company communications around the 2026 financing cite rapid year-over-year revenue gains. This momentum is positioned as evidence of increasing commercial adoption.
Market Expansion: Public materials reference a growing base of hundreds of organizations and new health-system partnerships announced in 2026. Ongoing hiring and new launches in May 2026 indicate active go-to-market execution.
